EyePoint: DURAVYU's Durability Could Drive Significant Upside

DURAVYU, EyePoint's lead candidate for wet AMD and DME, has demonstrated a compelling durability profile in Phase 2. Read why ...

4D Molecular Therapeutics Touts Rapid Phase 3 Momentum for Retinal Gene Therapy

D Molecular Therapeutics (NASDAQ:FDMT) executives said the company is seeing strong clinical trial momentum for its lead retinal gene therapy candidate, 4D-150, as it advances through late-stage devel ...

Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma

The trial did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS) A numeric improvement ...

Regeneron Pharmaceuticals, Inc.: Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma

The trial did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS) A numeric improvement of 5.1 months in median PFS was observed for the high- ...

EyePoint's late-stage eye drug trials to continue after safety panel review

EyePoint said on Thursday an independent safety committee found no new concerns in ​two late-stage trials of its experimental eye disease drug ‌Duravyu and recommended the studies continue unchanged.